Ownership Submission
FORM 3
 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0104
Expires: January 31, 2005
Estimated average burden hours per response... 0.5

(Print or Type Responses)
1. Name and Address of Reporting Person *
  SEIKKULA LUKE
 2. Date of Event Requiring Statement (Month/Day/Year)
02/22/2007		 3. Issuer Name and Ticker or Trading Symbol
LA JOLLA PHARMACEUTICAL CO [LJPC]
(Last)
(First)
(Middle)
6455 NANCY RIDGE DRIVE		 4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
_____ Director _____ 10% Owner
__X__ Officer (give title below) _____ Other (specify below)
Vice President Manufacturing
 5. If Amendment, Date Original Filed(Month/Day/Year)
(Street)

SAN DIEGO, CA 92121		 6. Individual or Joint/Group Filing(Check Applicable Line)
_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
(City)
(State)
(Zip)
Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security
(Instr. 4)		 2. Amount of Securities Beneficially Owned
(Instr. 4)		 3. Ownership Form: Direct (D) or Indirect (I)
(Instr. 5)		 4. Nature of Indirect Beneficial Ownership
(Instr. 5)
Common Stock 2,718
D
 

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. SEC 1473 (7-02)
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security
(Instr. 4)		 2. Date Exercisable and Expiration Date
(Month/Day/Year)		 3. Title and Amount of Securities Underlying Derivative Security
(Instr. 4)		 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 5)		 6. Nature of Indirect Beneficial Ownership
(Instr. 5)
Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Options (right to buy)   (1) 10/01/2011 Common Stock 700 $ 20.3 D  
Stock Options (right to buy)   (2) 12/14/2011 Common Stock 480 $ 35.5 D  
Stock Options (right to buy)   (2) 07/18/2012 Common Stock 460 $ 25.45 D  
Stock Options (right to buy)   (2) 11/21/2012 Common Stock 660 $ 29.5 D  
Stock Options (right to buy)   (2) 05/12/2013 Common Stock 750 $ 14.85 D  
Stock Options (right to buy)   (2) 09/18/2013 Common Stock 750 $ 23.55 D  
Stock Options (right to buy)   (3) 05/21/2014 Common Stock 1,599 $ 14.8 D  
Stock Options (right to buy)   (4) 07/29/2014 Common Stock 100 $ 10.6 D  
Stock Options (right to buy)   (5) 04/25/2015 Common Stock 2,646 $ 2.4 D  
Stock Options (right to buy)   (5) 05/19/2015 Common Stock 1,354 $ 2.15 D  
Stock Options (right to buy)   (5) 10/10/2015 Common Stock 5,414 $ 4.2 D  
Stock Options (right to buy)   (5) 04/17/2016 Common Stock 20,301 $ 4.46 D  
Stock Options (right to buy)   (6) 02/05/2017 Common Stock 25,000 $ 3.08 D  

Reporting Owners

Reporting Owner Name / Address Relationships
Director 10% Owner Officer Other
SEIKKULA LUKE
6455 NANCY RIDGE DRIVE
SAN DIEGO, CA 92121		       Vice President Manufacturing  

Signatures

/s/ Gail A. Sloan Attorney-in-fact for Luke Seikkula 03/01/2007
**Signature of Reporting Person Date

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 5(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1) The stock options vested and became exercisable with respect to 33% of the underlying shares on 10/1/2002 and with respect to an additional 67% of the underlying shares monthly during the following 2 years.
(2) 1/36 of the stock options vested and became exercisable each month following the grant date.
(3) 1/2 of the stock options vest on the date that the Company receives approval to market its lead drug candidate for the treatment of lupus and 1/24 of the remaining stock options vest at the end of each month thereafter until all of the stock options are vested. Notwithstanding the foregoing, if marketing approval is not obtained between the grant date and the three year anniversary of the grant date, then 100% of the stock options will vest on the three year anniversary of the grant date.
(4) The stock options vested and became exercisable on the grant date.
(5) 1/36 of the stock options vest and become exercisable each month following the grant date.
(6) 1/48 of the stock options vest and become exercisable each month following the grant date.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.